Coronary artery disease progression is associated with C-reactive protein and conventional risk factors but not soluble CD40 ligand

Canadian Journal of Cardiology

Volumn 22, Issue 8, 2006, Pages 691-696

  Liang, Kae Woei ^a,b   Sheu, Wayne Huey Herng ^a,c   Lee, Wen Lieng ^a,b   Liu, Tsun Jui ^a,b   Ting, Chih Tai ^a,b   Chen, Ying Tsung ^a,b,c   Lee, Wen Jane ^a,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d TUNGHAI UNIVERSITY   (Taiwan)

Author keywords

Adhesion molecules; CAD progression; CD40 ligand; CRP; Inflammatory markers; MCP 1

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CD40 LIGAND; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEART CATHETERIZATION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SENSITIVITY ANALYSIS; SEX DIFFERENCE; STABLE ANGINA PECTORIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33746421465     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(06)70938-2     Document Type: Article

References (33)

1. Libby P. What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol 2001;88(7B):3J-6J.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
4. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 1987;257:2176-80.
5. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-8.
6. Libby P, Ridker PM. Inflammation and atherosclerosis: Role of C-reactive protein in risk assessment. Am J Med 2004;116(Suppl 6A):9S-16S.
7. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994;90:775-8.
8. Poston RN, Haskard DO, Coucher JR, Gall NP, Johnson-Tidey RR. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol 1992;140:665-73.
9. Schonbeck U, Libby P. CD40 signing and plaque instability. Circ Res 2001;89:1092-103.
10. Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: Risk prediction after acute coronary syndromes. Circulation 2003;108:1049-52.
11. de Lemos JA, Morrow DA, Sabatine MS, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003;107:690-5.
12. Cipollone F, Marini M, Fazia M, et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 2001;21:327-34.
13. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 2003;108:1917-23.
14. Varo N, Vicent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: A novel target of thiazolidinediones. Circulation 2003;107:2664-9.
15. Garlichs CD, John S, Schmeisser A, et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 2001;104:2395-400.
16. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-11.
17. Cipollone F, Ferri C, Desideri G, et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 2003;108:2776-82.
18. Frey N, Dietz A, Kurowski V, et al. Angiographic correlates of a positive troponin T test in patients with unstable angina. Crit Care Med 2001;29:1130-6.
19. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983;51:606.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
21. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 2001;104:2266-8.
22. de Lemos JA, Zirlik A, Schonbeck U, et al. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: Results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2005;25:2192-6.
23. Verma S, Wang CH, Li SH, et al. The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers. Atherosclerosis 2005;182:361-5.
24. Aukrust P, Ueland T, Muller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998;97:1136-43.
25. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
26. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
27. Zairis MN, Manousakis SJ, Stefanidis AS, et al. C-reactive protein and rapidly progressive coronary artery disease - Is there any relation? Clin Cardiol 2003;26:85-90.
28. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
29. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998;351:88-92.
30. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997;96:4219-25.
31. Mizia-Stec K, Zahorska-Markiewicz B, Mandecki T, Janowska J, Szulc A, Jastrzebska-Maj E. Serum levels of selected adhesion molecules in patients with coronary artery disease. Int J Cardiol 2002;83:143-50.
32. Lee WL, Sheu WH, Liu TJ, et al. The short-/intermediate-term changes in novel vascular inflammatory markers after angioplasty plus stenting in patients with symptomatic advanced systemic arterial diseases. Atherosclerosis 2004;176:125-32.
33. Zouridakis E, Avanzas P, Arroyo-Espliguero R, et al. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004;110:1747-53.